AndreaBozzo/ceres-open-data-index huggingface dataset:
V-safe RSV for Adults

Users of the V-safe data are required to adhere to the following standards for the analysis and reporting of research data. All research results must be presented and/or published in a manner that protects the confidentiality of participants. V-safe data will not be presented and/or published in any way in which an individual can be identified. Therefore, users will:<ol>
<li>Not attempt to link or permit others to link the data with individually identified records in another database.
<li>Not attempt to learn the identity of any participant in the data and will not deliberately combine these data with other CDC or non-CDC data for the purpose of matching records to identify individuals. If you should inadvertently discover the identity of any participant, you will ensure the identity of any participant is kept confidential, and will not be used in any publications and/or presentations.
<li>Not imply or state, either in written or oral form, that interpretations based on analysis of the data reflect official CDC policies or positions.
<li>Understand that sub-national analyses are not appropriate for this national sample and will not be conducted. 
<li>Understand that V-safe is a voluntary self-enrollment program requiring smartphone access; therefore, information from V-safe might not be representative or generalizable to the US population.</li></ol>
By clicking on the weblink below to download and use these V-safe data, you signify your agreement to comply with the above-stated terms.

V-safe is a voluntary U.S. active safety surveillance system established by CDC to characterize local and systemic side effects of new vaccines administered after U.S. authorization or licensure. V-safe participants are not a random sample of all vaccinated persons in the United States and data might not be generalizable to the full U.S. vaccinated population. Participants may have been more likely to complete surveys if experiencing symptoms post-vaccination. All V-safe measures are self-reported, therefore there may be some misclassification of outcomes, vaccine-related information, or demographics.

For participants who requested corrections (i.e. vaccination date or vaccine manufacturer) to their vaccination record, data may be missing or incorrect for one or more doses. Requested corrections were applied to ‘Enrollment’ and ‘Vaccination’ files. The old vaccination records are located in the ‘Vaccination (Old Records)’ file while the corrected vaccine records are in the ‘Vaccination’ file. Mobile outages or technical malfunctions may have caused a small number of missing surveys or collection of incorrect survey type. Occasional system outages and attrition over time also contribute to incomplete reporting. 

V-safe RSV for Adults public data includes enrollment, vaccination information, and daily and weekly surveys collected from 10/20/2023 to 3/23/2025. Corresponding V-safe Registration public data (de-identified demographic data) can be downloaded at data.cdc.gov. Please review the V-safe data user agreement before analyzing any V-safe data.
Patent AT-E400830-T1: [Translated] OPTICAL OPTION MOUNTING RING

The optical option attachment ring (10) of the present invention includes a rotator (40) having an abutting surface (41) that projects inward from the inner circumferential surface (20a) of the ring body (20) and abuts the front end (31) of the lens barrel (30) as well as an arcuate portion (42) that follows the upper end of the abutting surface (41). The optical option attachment ring (10) further includes a resilient member (B) that applies an urging force to the rotator (40) to rotate in the direction opposite to the above-mentioned rotation direction and a stopper (45) that abuts at least one of the one end (21) and the other end (22) so as to restrict the rotation caused by the urging force of the resilient member (B).
Quinidine gluconate

Quinidine Gluconate is a prescription medication available as an extended-release tablet (324 mg) for oral use. It acts as an antiarrhythmic drug to help regulate heart rhythm, particularly in cases of atrial fibrillation or ventricular arrhythmias. Manufactured by Sun Pharmaceutical Industries, Inc., it's a generic version approved under ANDA 089338. This information was generated using AI and is provided for informational and research purposes only.
Comparing and Evaluating Substance Use Treatment Utilization Estimates from the National Survey on Drug Use and Health and Other Data Sources

This report presents an evaluation of the coverage, overlap, biases, strengths, and weaknesses of three sources of data on the receipt of specialty substance use treatment: the National Survey on Drug Use and Health (NSDUH), the National Survey of Substance Abuse Treatment Services (N-SSATS), and the Treatment Episode Data Set (TEDS). Specialty substance use treatment measures compared include numbers and characteristics of persons treated in a given year, single-day treatment counts, numbers of admissions in a given year, and estimates of the numbers of persons who needed substance use treatment but did not receive it. This report includes data from the 2005 through 2010 NSDUHs; 2007 through 2009 N-SSATS; and 2007 through 2009 TEDS. Results are show by substance treated, age, race/ethnicity, and employment status,
NNDSS - TABLE 1FF. Severe acute respiratory syndrome-associated coronavirus disease to Shigellosis

NNDSS - TABLE 1FF. Severe acute respiratory syndrome-associated coronavirus disease to Shigellosis – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Patent AT-E40139-T1: [Translated] PROCESS FOR THE PRODUCTION OF PURE ANDROST-2ENDED DERIVATIVES.

1. A process for producing a DELTA-2 androstenic derivative in the pure state form a mixture of DELTA-2(3) and DELTA-3(4) androstene characterized in that a mixture of Androstenes of the formula  see diagramm : EP0200591,P8,F1  wherein the dotted line symbolizes a double bond in the position 2(3) or 3(4) R is a, free esterified with an organic acid having from 1 to 10 carbon atoms or etherified with an alkyl radical or a tetrahydropyranyl, hydroxyl group R' is hydrogen, a lower alkenyl radical, a lower alkynyl radical, a lower alkyl radical a phenyl radical or a cycloalkyl radical or R and R' together are the oxygen of a ketonic group and the wawed line indicates the spatial orientation alpha or beta is submitted to the action of a sulfonating agent pure or in an inert solvent in the optional presence of a dehydrating agent, to obtain a DELTA-3 Androstenyl 2-sulfonic acid of the general formula II  see diagramm : EP0200591,P8,F3  in which R and R' have the previously given meanings and recovers the pure DELTA-2 androstenic derivative, unaltered having the general formula IV  see diagramm : EP0200591,P8,F2 wherein the substituents R and R' are defined as previous by given.
Furosemide

Furosemide is a prescription loop diuretic used to treat conditions like edema (fluid retention) and high blood pressure by increasing urine production. This injectable solution (10 mg/mL) is administered intravenously and comes in 4 mL single-dose vials, packaged in boxes of 25. Manufactured by Baxter Healthcare Corporation and Civica, Inc., under application ANDA202747. This information was generated using AI and is provided for informational and research purposes only.
Compound 529249: 1-Pyrroline, 2-butanoyl

Chemical compound data from PubChem database. IUPAC Name: 1-(3,4-dihydro-2H-pyrrol-5-yl)butan-1-one. Molecular Formula: C8H13NO. Molecular Weight: 139.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530646: p-Toluic acid, hex-4-yn-3-yl ester

Chemical compound data from PubChem database. IUPAC Name: hex-4-yn-3-yl 4-methylbenzoate. Molecular Formula: C14H16O2. Molecular Weight: 216.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table II. Shiga toxin to Shigellosis

NNDSS - Table II. Shiga toxin to Shigellosis - 2015.  In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable.    NP: Nationally notifiable but not published.    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. �� Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
National Substance Use And Mental Health Services Survey (N-SUMHSS): 2022 Data On Substance Use And Mental Health Treatment Facilities

This report presents results from the 2022 National Substance Use and Mental Health Services Survey (N-SUMHSS), an annual survey of substance use and mental health treatment facilities in the United States. Conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), the N-SUMHSS is designed to collect data on the location, characteristics, service provision and utilization of substance use and mental health treatment facilities.
Compound 525369: 2,4,4-Trimethyl-3-thiahexane

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-2-propan-2-ylsulfanylbutane. Molecular Formula: C8H18S. Molecular Weight: 146.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2012 Uniform Reporting System (URS) Tables for Iowa

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E40172-T1: [Translated] HINGE.

A hinge joint comprises a hinge leaf, a closure element, a knuckle bearing, a hinge bolt defining a hinge joint axis and pivotally mounting the closure element via the knuckle bearing, a hinge bearing having a base securable adjacent to an edge of an opening, the hinge bearing having legs between which the knuckle bearing is positioned and which carries the hinge bolt, the knuckle bearing having at least one first protrusion extending axially outwardly and arranged concentrically relative to the hinge bolt, one of the legs having an axially inwardly extending protrusion which axially overlaps the first protrusion, the hinge leaf together with the closure element being arranged so that it can be removed from the hinge bearing only after removal of the hinge bolt and after opening the closure element through a predetermined pivot angle, the first protrusion being annular, the second protrusion being formed as an enclosing retainer of one of the legs and arranged radially outside of one of the first protrusions, the enclosing retainer at at least one side face of the leg being provided with an access passage for the first protrusion, and cam means provided on the hinge leaf, so that only in a pivoted position of the closure element is a minimum dimension of the cam means extending perpendicular to the hinge joint axis with the hinge bolt removed, so that the passage of the first protrusion through an associated one of the access passages is possible.
CDC WONDER: Population - Bridged-Race July 1st Estimates

<p>The Population - Bridged-Race July 1st Estimates online databases report bridged-race population estimates of the July 1st resident population of the United States, based on Census 2000 counts, for use in calculating vital rates. These estimates result from "bridging" the 31 race categories used in Census 2000, as specified in the 1997 Office of Management and Budget (OMB) standards for the collection of data on race and ethnicity, to the four race categories specified under the 1977 standards (Asian or Pacific Islander, Black or African American, American Indian or Alaska Native, White). Many data systems, such as vital statistics, are continuing to use the 1977 OMB standards during the transition to full implementation of the 1997 OMB standards. Postcensal estimates are available for year 2000 - 2009; intercensal estimates are available for the years 1990-1999.  Obtain population counts by  Year, State, County, Race (4-categories), Ethnicity, Sex and Age (1-year or 5-year groups).   The data are released by the National Center for Health Statistics.</p>
COVID-19 Community Profile Report

<b>After over two years of public reporting, the Community Profile Report will no longer be produced and distributed after February 2023. The final release will be on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The Community Profile Report (CPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, under the White House COVID-19 Team. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services, the Centers for Disease Control and Prevention, the Assistant Secretary for Preparedness and Response, and the Indian Health Service). The CPR  provides easily interpretable information on key indicators for all regions, states, core-based statistical areas (CBSAs), and counties across the United States. It is a snapshot in time that:       
<li>Focuses on recent COVID-19 outcomes in the last seven days and changes relative to the week prior              
<li> Provides additional contextual information at the county, CBSA, state and regional levels               
<li> Supports rapid visual interpretation of results with color thresholds*
</p>

<p>Data in this report may differ from data on state and local websites. This may be due to differences in how data were reported (e.g., date specimen obtained, or date reported for cases) or how the metrics are calculated. Historical data may be updated over time due to delayed reporting. Data presented here use standard metrics across all geographic levels in the United States. It facilitates the understanding of COVID-19 pandemic trends across the United States by using standardized data.  The footnotes describe each data source and the methods used for calculating the metrics. For additional data for any particular locality, visit the relevant health department website. Additional data and features are forthcoming.</p>

*Color thresholds for each category are defined on the color thresholds tab



Effective April 30, 2021, the Community Profile Report will be distributed on Monday through Friday. There will be no impact to the data represented in these reports due to this change. 

Effective June 22, 2021, the Community Profile Report will only be updated twice a week, on Tuesdays and Fridays.

Effective August 2, 2021, the Community Profile Report will return to being updated Monday through Friday. 

Effective June 22, 2022, the Community Profile Report will only be updated twice a week, on Wednesdays and Fridays.
2015 CMHS Uniform Reporting System (URS) Table for North Dakota

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for North Dakota.  The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
PLACES: Place Data (GIS Friendly Format), 2023 release

This dataset contains model-based place (incorporated and census designated places) estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia —at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2021 or 2020 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2023 release uses 2021 BRFSS data for 29 measures and 2020 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours) that the survey collects data on every other year. These data can be joined with the 2019 Census TIGER/Line place boundary file in a GIS system to produce maps for 36 measures at the place level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software.
https://cdcarcgis.maps.arcgis.com/home/item.html?id=2c3deb0c05a748b391ea8c9cf9903588
Compound 527282: Citronellyl heptanoate

Chemical compound data from PubChem database. IUPAC Name: 3,7-dimethyloct-6-enyl heptanoate. Molecular Formula: C17H32O2. Molecular Weight: 268.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Alaska 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 530172: Tris(trimethylsilyl)guanine

Chemical compound data from PubChem database. IUPAC Name: N,9-bis(trimethylsilyl)-6-trimethylsilyloxypurin-2-amine. Molecular Formula: C14H29N5OSi3. Molecular Weight: 367.67. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.